Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237 - Wikidata - awgldk - TriplyDB

Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237

Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237

http://www.wikidata.org/entity/Q27660936

about

Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer A Cell Biologist's Field Guide to Aurora Kinase Inhibitors Development of o -Chlorophenyl Substituted Pyrimidines as Exceptionally Potent Aurora Kinase Inhibitors Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules Completing the structural family portrait of the human EphB tyrosine kinase domains Molecular mechanism of Aurora A kinase autophosphorylation and its allosteric activation by TPX2 The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells Hydrophobic Core Variations Provide a Structural Framework for Tyrosine Kinase Evolution and Functional Specialization 'Up with the LRRK': a phosphorylated Rab10 assay for evaluation of LRRK2 activity and inhibitor engagement SERS and MD simulation studies of a kinase inhibitor demonstrate the emergence of a potential drug discovery tool Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL Cell biology. Reversible centriole depletion with an inhibitor of Polo-like kinase 4.Proteasome regulates the mediators of cytoplasmic polyadenylation signaling during late-phase long-term potentiation.Tripolin A, a novel small-molecule inhibitor of aurora A kinase, reveals new regulation of HURP's distribution on microtubules.Multiplex imaging and cellular target identification of kinase inhibitors via an affinity-based proteome profiling approach.Issues in interpreting the in vivo activity of Aurora-A DNA replication stress in CHK1-depleted tumour cells triggers premature (S-phase) mitosis through inappropriate activation of Aurora kinase B.Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.Aurora-A inactivation causes mitotic spindle pole fragmentation by unbalancing microtubule-generated forces Aurora A and Aurora B jointly coordinate chromosome segregation and anaphase microtubule dynamics.Activation of Aurora-A kinase by protein partner binding and phosphorylation are independent and synergistic A functional cooperativity between Aurora A kinase and LIM kinase1: implication in the mitotic process Pten regulates Aurora-A and cooperates with Fbxw7 in modulating radiation-induced tumor development.The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing.Bioorthogonal imaging of aurora kinase A in live cells Aurora A is involved in central spindle assembly through phosphorylation of Ser 19 in P150Glued Detection of Ligand-induced Conformational Changes in the Activation Loop of Aurora-A Kinase by PELDOR Spectroscopy Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10).The structural mechanisms that underpin mitotic kinase activation.KinView: a visual comparative sequence analysis tool for integrated kinome research.Aurora A kinase activity is required for localization of TACC3/ch-TOG/clathrin inter-microtubule bridges.Molecular basis underlying resistance to Mps1/TTK inhibitors.Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy.Tetraploidization increases sensitivity to Aurora B kinase inhibition.Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.Unblocking the sink: improved CID-based analysis of phosphorylated peptides by enzymatic removal of the basic C-terminal residue.Long residence times revealed by Aurora A kinase-targeting fluorescent probes derived from inhibitors MLN8237 and VX-689.Plk4 and Aurora A cooperate in the initiation of acentriolar spindle assembly in mammalian oocytes.

P2860

Q24296639-17C19EBE-031F-4AC6-B651-09842027BACE Q26784060-8BD6DD44-BBB2-442D-8763-AD123DD23A3E Q27308125-71B06708-E48F-479C-8052-37E38AA751B8 Q27670770-10D61609-E524-4181-85F1-BD38E089AA2A Q27677506-307A3BC1-71D5-404F-9F66-8516BE4BE78B Q27682624-37855AA1-58AC-41CD-B762-5D7EB92E9BD2 Q27683971-01BD1F44-B432-44F2-BFE8-A70694881477 Q27851718-9BE11B2B-8A9E-4635-B385-2E8DC4832FCB Q28545195-DDE428E2-F910-4D6F-8E2A-0B721CB7CA98 Q28550424-D528B821-1DDB-4B12-8257-C871F0B190E5 Q28822157-AE062147-65AF-4CB7-BE57-262528C8C599 Q33971948-3C0737DB-CC64-44A8-AD10-699B84A11476 Q34365833-08A3A971-6FA2-4885-916E-BC3AAAD69AF2 Q34474551-3DA48AB2-1384-4D50-8AED-4FFE606D0CC4 Q34615714-8FE9DE73-557C-456E-A4C8-5CC395F09B16 Q34629643-1215D470-3D8A-4F83-A887-A2C7C38F476E Q34908239-C661AFA1-246F-4B9B-B15C-F318D9B0C83C Q34964087-B6B9FFFD-F73A-4187-B131-FF366B9DA88B Q35172709-C916444D-B2F7-4F28-8627-D7EA0732D792 Q35549470-71B40FF2-6287-4607-9A58-A3CF490A24EF Q35579730-3F0FB03D-63D0-419E-8ED3-451A1B503ADD Q35636568-3BCDAB76-76A8-4B9F-8DCA-4F661BDD376D Q35668733-DAEF0D57-15C8-4422-A0C3-EE2598CBD0E3 Q35801399-2E27C161-2BB7-4B5C-BC87-6C576FF63178 Q36071656-16A30F52-5FE9-4190-9446-88AAF9C12F21 Q36451580-05F33A5D-4BC6-4F0A-B6AB-705D4A068D69 Q36470833-DE8B10AF-DE1F-4E53-8DC0-4712C660A16E Q36732768-3063AE32-294D-4668-B9D0-1E8CC4974D74 Q37515396-CE4B877B-3772-4F69-943D-51922C0799EE Q37876882-3686FA62-D1FF-4EC8-9350-1FD77FEB5D07 Q38122237-88B055F5-63FA-4119-AB18-698737C48329 Q38407314-0A60E9B0-89A5-47AF-BB39-E3F0EF058B98 Q38577155-20EEC954-9A69-4BED-B165-1195718CCE98 Q38835748-89A24C26-1499-487E-B904-F19843CD1015 Q38894287-F5B3D554-E16A-4897-9FF9-D645A4DB7A5A Q39327085-50509C15-4628-4AB8-ACFD-109B83C0D597 Q39388577-6FCEFB1E-B268-40C0-A187-8BC2D6BC90BD Q41886466-EA5CEAE4-59B5-4516-9BB8-E8D0B98B1991 Q46264711-D4F662FA-BA4F-470E-9A24-14B49E26132A Q47149424-C1C4E017-9B1E-4C3D-8973-17978BE2E492

P2860

Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237

http://www.wikidata.org/entity/Q27660936

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Drug-resistant aurora A mutant ...... inhibitors MLN8054 and MLN8237

@ast

Drug-resistant aurora A mutant ...... inhibitors MLN8054 and MLN8237

@en

Drug-resistant aurora A mutant ...... inhibitors MLN8054 and MLN8237

@nl

type

label

Drug-resistant aurora A mutant ...... inhibitors MLN8054 and MLN8237

@ast

Drug-resistant aurora A mutant ...... inhibitors MLN8054 and MLN8237

@en

Drug-resistant aurora A mutant ...... inhibitors MLN8054 and MLN8237

@nl

prefLabel

Drug-resistant aurora A mutant ...... inhibitors MLN8054 and MLN8237

@ast

Drug-resistant aurora A mutant ...... inhibitors MLN8054 and MLN8237

@en

Drug-resistant aurora A mutant ...... inhibitors MLN8054 and MLN8237

@nl

P1433

Q27660936-7C9A31DB-A894-4C3B-81EC-D55FD6B0491C

P1476

Q27660936-C9CC5D0F-1E52-4289-8715-5607E8B2E131

P2093

Q27660936-05375C93-8B4F-484E-97C3-5740624D360B

Q27660936-06D2368D-6EB2-4C51-A5D1-D35050E70FBB

Q27660936-4C7F8A22-C7F7-435F-8B05-080C109D295C

Q27660936-59D815F1-6280-4C6E-A070-6CF54EE11BDF

Q27660936-9B2D3863-33EB-48CF-9CC0-EDAD1CAC3CE0

Q27660936-B98FE764-D9BA-46D8-9B27-11DAAEF3FF26

Q27660936-C2213EFA-1E3B-4359-AC02-38B48A92203B

Q27660936-C4E9320C-EA04-47D6-8ADE-B982A386EFD4

Q27660936-D44084FE-974F-477D-B3E1-AAF5621A3251

P304

Q27660936-8603B661-BF86-4DC4-A9E4-F0BBF7BA0582

P31

Q27660936-3400CA6C-6381-44B1-99E8-8CD93F454B3F

P3181

Q27660936-8BDE7510-97DD-44F9-BA2A-3FCCC21EC632

P356

Q27660936-C5501A41-389F-455A-A25D-2A256550935D

P433

Q27660936-3B6D702A-B542-45B4-BF84-645006526BA4

P478

Q27660936-1A03B667-DC46-43E0-BA9E-A1A5F15965D7

P577

Q27660936-D9E3173C-64D5-4F70-91EA-167E26B3CA61

P5875

Q27660936-57FCF9B2-08F9-4F5D-A248-6C195FF86205

P698

Q27660936-2B17E5F4-8EE0-4CCF-9F95-5DE7356F7494

P3181

P356

P1433

ACS Chemical Biology

P1476

Drug-resistant aurora A mutant ...... inhibitors MLN8054 and MLN8237

@en

P2093

Clive S Mason

http://www.w3.org/2001/XMLSchema#string

David H Williams

http://www.w3.org/2001/XMLSchema#string

Dominic A Sloane

http://www.w3.org/2001/XMLSchema#string

Ilka Mueller

http://www.w3.org/2001/XMLSchema#string

Maria B A C Lamers

http://www.w3.org/2001/XMLSchema#string

Matthew L H Chu

http://www.w3.org/2001/XMLSchema#string

Michael Z Trikic

http://www.w3.org/2001/XMLSchema#string

Patrick A Eyers

http://www.w3.org/2001/XMLSchema#string

Wendy J Savory

http://www.w3.org/2001/XMLSchema#string

P304

563-76

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3745020

http://www.w3.org/2001/XMLSchema#string

P356

10.1021/CB100053Q

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43350539

http://www.w3.org/2001/XMLSchema#string

P698

20426425

http://www.w3.org/2001/XMLSchema#string